TP53 had the second highest prevalence (n = 6; 0.76%), with patients showing a variety of different tumor types, including soft-tissue sarcomas, osteosarcoma, leukemia, and carcinoma (in this case an ACT). This evidence concerns the gene TP53 and leukemia.